AlphAIalphai — Financial news for AI agents
aol.comAUG 233 min read$KYNB

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) reported Q2 2026 earnings with revenue of -$1.5M, net income of $12.0M, and $95.7M in cash. Clinical updates include FG-3246 Phase II enrollment and roxadustat Phase III plans. Management expects cash to last into 2028 and discussed potential partnerships for roxadustat.

Original reporting
aol.com
Published Aug 23, 2026, 3:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 23, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$KYNBBullishMed
01

Why it matters

Earnings beat and cash runway provide short-term buying interest; clinical milestones could drive longer-term valuation.

02

Market read

Kyntra Bio's earnings release is a primary catalyst for its stock, with potential spillover to the biotech sector.

03

What to watch

Potential dilution from future financing needs beyond 2028 runway.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Kyntra Bio presented its Q2 2026 financial results and updates on FG-3246 and roxadustat programs.

Company-level read

Ticker impact

$KYNBBullishHigh confidence
Context

Q2 2026 earnings call disclosed net income of $12.0M, revenue of -$1.5M and cash of $95.7M, plus clinical trial updates.

Expected impact

Potential upside of 5-10% in the next few days as investors digest earnings and trial progress.

Evidence & confidence

Earnings beat and cash runway to 2028 are material for a small-cap biotech; trial data adds catalyst.

Market effects

Sector

Positive earnings may lift other early-stage oncology biotech stocks.

Regional

US biotech sector gains modestly.

Global

Limited to investors tracking small-cap biotech developments.

Counterpoint

What could challenge this read

Earnings may be a one-time cash boost; clinical data still early and could face setbacks.

Key entities

  • Executive
    Thane Wettig

    CEO of Kyntra Bio

  • Executive
    David DeLucia

    CFO of Kyntra Bio

Read at source← All news

Related articles

SEP 1
$KYNBMed

Oppenheimer reiterates Kyntra Bio stock rating on debt reduction

Oppenheimer maintained an Outperform rating and $35.00 price target for Kyntra Bio (NASDAQ:KYNB) after the company restructured its royalty financing agreement, reducing obligations to $65M from $125M. The company made a $42.6M payment, eliminating $60M in future obligations while retaining royalty economics. Kyntra Bio has a current ratio of 2.69 and is trading at $7.78, below analyst targets. Oppenheimer expects Phase 3 and Phase 2 data in 2026 and sees improved financial flexibility.

investing.com2 min
AUG 20
$KYNBMedAI 8/10

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Kyntra Bio (KYNB) reported Q2 2026 revenue of -$1.5M, a net income of $12.0M, and $95.7M in cash. Clinical trials for FG-3246 in prostate cancer and roxadustat in MDS showed progress. Operating expenses rose to $16.1M. Management expects cash to last into 2028 and is evaluating partnership options for roxadustat.

fool.com2 min
AUG 13
$KYNBMed

KYNTRA BIO, INC. (KYNB): Results of Operations and Financial Condition

KYNTRA BIO, INC. (KYNB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update • Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues

SEC EDGAR 8-K6 min
SEP 3
$SNOWHighAI 9/10

Snowflake Shares Rocket 20% As Q2 Earnings Beat And Guidance Raise Fuel One Of Its Biggest Rallies Since IPO

Snowflake Inc. shares rose 20.6% after Q2 earnings beat estimates, with adjusted EPS at 62 cents vs. 45-cent consensus and revenue at $1.55B vs. $1.48B expected. Product revenue grew 37% YoY to $1.49B. The company raised its full-year product revenue guidance to $6.1B, up from $6.05B. Strong adoption of AI tools drove results, with 9,100 customer accounts for Cortex Code. Analysts remain largely bullish, with 46 of 52 recommending buy or strong buy.

ibtimes.com.au2 min
SEP 3
$TTDMedAI 8/10

Can The Trade Desk's JBPs Become Its Next Major Growth Engine?

The Trade Desk reported 217 joint business partnerships (JBPs) in Q2 2026, up 38% YoY, with JBP revenues growing six times faster than overall revenue. Management highlights JBPs as a key growth driver amid macroeconomic pressures and execution challenges. Q2 revenue was $715M, up 3% YoY, with CPG and automotive sectors facing headwinds. The company expects Q3 revenue of at least $650M and adjusted EBITDA of $160M.

yahoo.com3 min
SEP 3
$TTCHigh

The Toro Company Reports Higher Earnings In Q3, Raises FY26 Outlook

The Toro Company (TTC) reported Q3 earnings of $0.81 per share, up from $0.54 per share last year, with net sales rising to $1.226 billion. Adjusted earnings were $1.33 per share. The company raised its FY26 outlook, expecting net sales growth of 6.3% to 6.6% and adjusted EPS of $4.60 to $4.65. Pre-market, TTC was up 2.80% at $101.90.

rttnews.com2 min